In light of the COVID-19 pandemic, the Exogenix Laboratory is collaborating with the Bundeswehr Institute for Microbiology in Munich, Germany, to deliver siRNA molecules to mammalian cells, using its proprietary technology, inhibiting SARS-CoV-2 replication. 


Recently published research has highlighted the impact of genetics on metabolites and obesity. One of the regulating features governing the types of microbe in the intestine is a gene called FMO5. A series of very high impact, peer reviered research papers have shown a direct link between the expression of the gene FMO5 and obesity in mice. It is hypothesised that down-regulating FMO5 in humans may dramatically alter the way fat is stored, impacting upon body mass index, obesity and overall health.  Consequentlythe Exogenix lab is optimising ASO, gRNA and siRNA sequences to be active in mice, as well as optimising the delivery of these sequences to the target cells, whilst developing its proprietary technology. This work is a collaboration between the Exogenix Laboratory, and Prof. Jeremy Everett of the Medway Metabolomic Research Group.



Zika Virus is spread from human to human through the bite of the Mosquitoe and there is currently no treatment for its infection. The Exogenix lab is developing a genomic treatment that can not only prevent the replication of the zika virus but also halt viral replication, enabling the immune system to eradicate the infection at an accelerated rate. Zika Virus relies on the expression of several genes critical to its reproduction once it is inside human cells causing a productive infection. 

The Exogenix lab has demonstrated that by using siRNA designed to target viral sequence, it can protect cells from Zika virus induced toxicity. 

The lab has delivered the siRNA using the Anthragenix and Exogenix platforms to cells infected with Zika (MR-766) and has preliminary data showing that it the technology can protect cells from virus induced cell kill. These experiments are being carried out in collaboration with Dr Joachim Bugert at the Bundeshwear Institute for Microbiology in Germany. 

© Exogenix Laboratory 2020